Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications.
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
11:54am, Thursday, 23'rd May 2024
Targeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
This Unpopular Dividend Stock Is a Buy
07:12am, Thursday, 23'rd May 2024
High-yield dividend stocks, on balance, are incredible value creators for long-term investors. Bristol Myers Squibb's yield has swelled to 5.6% this year, creating a compelling opportunity for patient
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
06:59am, Thursday, 23'rd May 2024
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT--Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
02:16pm, Wednesday, 22'nd May 2024
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
12:06pm, Wednesday, 22'nd May 2024
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
06:59am, Wednesday, 22'nd May 2024
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries.
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
03:30am, Wednesday, 22'nd May 2024
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON , May 22, 2024 /PRNewswire/ -- NeoPhore
Top Wall Street Strategist Sees 500 Point S&P 500 Drop – Buy 6 Passive Income Dividend Stocks Now
01:11pm, Tuesday, 21'st May 2024
Want to Retire Early?
3 Cheap and Dependable Dividend-Growth Stocks to Buy
11:52am, Tuesday, 21'st May 2024
These dividend growers look undervalued today.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #MentalHealthMonth--Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Cam
1 Stock I Wouldn't Touch With a 10-Foot Pole
08:15am, Tuesday, 21'st May 2024
Bristol Myers Squibb had a punishing first quarter. It's undergoing a new cost-cutting campaign as a result.
3 Bargain Stocks to Buy Now: May 2024
07:45am, Tuesday, 21'st May 2024
Since the bull market began in November 2022, growth stocks have outperformed value by a significant margin. Nevertheless, value S&P 500 sectors like financials and utilities have led over the past tw
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivo and hyaluronidase).
Insider Trading is Good News for These Stocks
09:45am, Monday, 20'th May 2024
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
